Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Non-Current Deffered Revenue (2016 - 2019)

Tvardi Therapeutics' Non-Current Deffered Revenue history spans 7 years, with the latest figure at $6.1 million for Q2 2019.

  • On a quarterly basis, Non-Current Deffered Revenue fell 79.92% to $6.1 million in Q2 2019 year-over-year; TTM through Jun 2019 was $6.1 million, a 79.92% decrease, with the full-year FY2019 number at $9.6 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $6.1 million in Q2 2019 for Tvardi Therapeutics, down from $9.6 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for TVRD hit a ceiling of $30.3 million in Q2 2018 and a floor of $585000.0 in Q4 2015.
  • Historically, Non-Current Deffered Revenue has averaged $4.4 million across 5 years, with a median of $1.6 million in 2016.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 1838.52% in 2018 and later tumbled 79.92% in 2019.
  • Tracing TVRD's Non-Current Deffered Revenue over 5 years: stood at $585000.0 in 2015, then soared by 168.38% to $1.6 million in 2016, then grew by 9.43% to $1.7 million in 2017, then skyrocketed by 783.82% to $15.2 million in 2018, then crashed by 59.92% to $6.1 million in 2019.
  • Business Quant data shows Non-Current Deffered Revenue for TVRD at $6.1 million in Q2 2019, $9.6 million in Q1 2019, and $15.2 million in Q4 2018.